LACEY VASILAKIS: Open Payments
NPI 1083056915 · LAKE CHARLES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,168 in 138 payments from 46 companies in 2025. Trend: 2023 $2,812 · 2024 $3,271 · 2025 $3,168
Food & beverage: $2,876Education: $292
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 8 | $274 |
| Novartis Pharmaceuticals Corporation | 13 | $253 |
| AstraZeneca Pharmaceuticals LP | 11 | $239 |
| Merck Sharp & Dohme LLC | 7 | $196 |
| Astellas Pharma US Inc | 6 | $187 |
| PFIZER INC. | 8 | $165 |
| Celgene Corporation | 7 | $139 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $111 |
| E.R. Squibb & Sons, L.L.C. | 6 | $109 |
| ABBVIE INC. | 5 | $106 |
Products named: Enhertu, KEYTRUDA, KISQALI, SARCLISA, REBLOZYL, OPDIVO, CALQUENCE, ELAHERE.
Industry payments across LA — which companies pay providers there.
